{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T23:40:01Z","timestamp":1759102801247,"version":"3.44.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,28]]},"DOI":"10.7759\/cureus.93429","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T23:09:15Z","timestamp":1759100955000},"source":"Crossref","is-referenced-by-count":0,"title":["Management of Glycogen-Rich Clear Cell Carcinoma of the Breast: A Case Report"],"prefix":"10.7759","author":[{"given":"Joshua S","family":"Braganza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baraah","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Presendieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadj L","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000341393","article-title":"Intraductal glycogen-rich clear cell carcinoma of the breast: a rare presentation and review of the literature","volume":"7","author":"Salemis NS","year":"2012","unstructured":"Salemis NS. Intraductal glycogen-rich clear cell carcinoma of the breast: a rare presentation and review of the literature. Breast Care (Basel). 2012, 7:319-21. 10.1159\/000341393","journal-title":"Breast Care (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.12231","article-title":"Clinicopathologic characteristics and prognosis of glycogen-rich clear cell carcinoma of the breast","volume":"20","author":"Ma X","year":"2014","unstructured":"Ma X, Han Y, Fan Y, Cao X, Wang X. Clinicopathologic characteristics and prognosis of glycogen-rich clear cell carcinoma of the breast. Breast J. 2014, 20:166-73. 10.1111\/tbj.12231","journal-title":"Breast J"},{"key":"ref3","article-title":"Glycogen-rich clear cell carcinomas of the breast: a clinicopathologic and ultrastructural study","volume":"10","author":"Hull MT","year":"1986","unstructured":"Hull MT, Warfel KA. Glycogen-rich clear cell carcinomas of the breast: a clinicopathologic and ultrastructural study. Am J Surg Pathol. 1986, 10:553-9.","journal-title":"Am J Surg Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000514978","article-title":"Genetic alterations in invasive breast carcinoma with a glycogen-rich clear cell pattern: a case report","volume":"14","author":"De la Sancha C","year":"2021","unstructured":"De la Sancha C, Ruiz-Cordero R, Popnikolov N. Genetic alterations in invasive breast carcinoma with a glycogen-rich clear cell pattern: a case report. Case Rep Oncol. 2021, 14:500-5. 10.1159\/000514978","journal-title":"Case Rep Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02715-z","article-title":"Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer","volume":"42","author":"de Heer EC","year":"2023","unstructured":"de Heer EC, Zois CE, Bridges E, et al.. Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer. J Exp Clin Cancer Res. 2023, 42:143. 10.1186\/s13046-023-02715-z","journal-title":"J Exp Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2017.02.044","article-title":"Glycogen-rich clear cell carcinoma (GRCC) of the breast may not have a poor prognosis","volume":"33","author":"Baslaim MM","year":"2017","unstructured":"Baslaim MM, Junainah EM, Ahmad HH, Semilan AF, Al-Ghamdi AO, Rahimuddin NO, Salman BA. Glycogen-rich clear cell carcinoma (GRCC) of the breast may not have a poor prognosis. Int J Surg Case Rep. 2017, 33:92-6. 10.1016\/j.ijscr.2017.02.044","journal-title":"Int J Surg Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.9956","article-title":"Glycogen-rich clear cell carcinoma of the breast with solid papillary pattern: two cases with heterogeneous clinicopathological features","volume":"21","author":"Georgescu TA","year":"2021","unstructured":"Georgescu TA, Munteanu O, Lisievici AC, et al.. Glycogen-rich clear cell carcinoma of the breast with solid papillary pattern: two cases with heterogeneous clinicopathological features. Exp Ther Med. 2021, 21:524. 10.3892\/etm.2021.9956","journal-title":"Exp Ther Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2463\/mrms.cr.2018-0012","article-title":"Clinical imaging of glycogen-rich clear cell carcinoma of the breast: a case series with literature review","volume":"18","author":"Eun NL","year":"2019","unstructured":"Eun NL, Cha YJ, Son EJ, Gweon HM, Kim JA, Youk JH. Clinical imaging of glycogen-rich clear cell carcinoma of the breast: a case series with literature review. Magn Reson Med Sci. 2019, 18:238-42. 10.2463\/mrms.cr.2018-0012","journal-title":"Magn Reson Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2012.53.6.1142","article-title":"Immunophenotypes of glycogen rich clear cell carcinoma","volume":"53","author":"Kim SE","year":"2012","unstructured":"Kim SE, Koo JS, Jung WH. Immunophenotypes of glycogen rich clear cell carcinoma. Yonsei Med J. 2012, 53:1142-6. 10.3349\/ymj.2012.53.6.1142","journal-title":"Yonsei Med J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231178125","article-title":"Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib\u2009+\u2009endocrine therapy versus endocrine therapy alone in patients with HR+\/HER2- early breast cancer","volume":"15","author":"Slamon DJ","year":"2023","unstructured":"Slamon DJ, Fasching PA, Hurvitz S, et al.. Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib\u2009+\u2009endocrine therapy versus endocrine therapy alone in patients with HR+\/HER2- early breast cancer. Ther Adv Med Oncol. 2023, 15:8125. 10.1177\/17588359231178125","journal-title":"Ther Adv Med Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/394511-management-of-glycogen-rich-clear-cell-carcinoma-of-the-breast-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T23:09:24Z","timestamp":1759100964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/394511-management-of-glycogen-rich-clear-cell-carcinoma-of-the-breast-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,28]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.93429","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,28]]}}}